

MAYNE PHARMA ANNOUNCES FDA APPROVAL OF NEW 200MG DORYX® TABLETS

12 April 2013, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has approved a 200mg strength of Doryx® (doxycycline hyclate) Delayed-Release Tablet. Warner Chilcott, the Company's marketing and distribution partner of Doryx® in the US, is expected to commence launch of this product by July 2013.

Doryx® Delayed-Release Tablets are a tetracycline-class oral antibiotic.

-ENDS-